Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Poster Schedule
All Days
Sun, Sep 8
Mon, Sep 9
Poster Schedule
Type here to filter the list
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
A001: Comparison of the Pharmacokinetics/Pharmacodynamics of a Fixed-Dose Combination of Rabeprazole/Magnesium Oxide 20/350 mg to the Enteric-Coated Rabeprazole 20 mg
Favorite
5:00 PM – 7:00 PM
ET
A002: A Comparative Review of Study Population & Dose Recommendations for In Vivo Bioequivalence Studies With Pharmacokinetic Endpoints Between FDA & EMA Guidances
Favorite
5:00 PM – 7:00 PM
ET
A003: Enhanced HLA-B*15:02 Screening Before Carbamazepine Therapy in Vietnam: Advancements in Real-Time PCR TaqMan Probe Procedure
Favorite
5:00 PM – 7:00 PM
ET
A004: Cefepime Population Pharmacokinetics Using Volumetric Absorptive Microsampling in Critically Ill Children With Multiple Organ Dysfunction Syndrome
Favorite
5:00 PM – 7:00 PM
ET
A005: Implications of Being Born Small for Gestational Age on the Exposure of Vancomycin & Gentamicin In Neonates
Favorite
5:00 PM – 7:00 PM
ET
A006: Microfluidic Blood-Milk Barrier & Physiologically-based Pharmacokinetic Model to Predict Lofexidine Secretion into Breast Milk
Favorite
5:00 PM – 7:00 PM
ET
A007: Dose Optimization of Cefazolin in Adult Cardiac Surgery With Cardiopulmonary Bypass After Albumin Supplementation
Favorite
5:00 PM – 7:00 PM
ET
A008: Using Clinical Data & Physiologically-based Pharmacokinetic Modelling to Assess the Effect of Hepatic Impairment on Avapritinib Pharmacokinetics to Guide Dose Adjustment
Favorite
5:00 PM – 7:00 PM
ET
A009: A Translational Platform Quantitative Systems Pharmacology Model for Preclinical to Clinical Translation of In Vivo CRISPR-Cas9 Gene Therapy
Favorite
5:00 PM – 7:00 PM
ET
A010: Model-Based Assessment of the Contribution of Fc Proteins & Serum Proteins to the Elevated Clearance of Monoclonal Antibodies
Favorite
5:00 PM – 7:00 PM
ET
091: Clinical Pharmacology of Bispecific T-cell Engagers: A Summary Based on FDA Approvals
Favorite
5:00 PM – 7:00 PM
ET
092: Concentration-QTc Interim Analysis of I-DXd in Subjects With Advanced Solid Tumors from Study IDeate-Pantumor01 (DS7300-A-J101)
Favorite
5:00 PM – 7:00 PM
ET
093: Trends in First-in-Human Trials of Intrathecal Antisense Oligonucleotide Therapies: Insights into Dose Selection, Dose Escalation & Early Clinical Development
Favorite
5:00 PM – 7:00 PM
ET
094: Analyzing First-in-Human Trial Designs of Antisense Oligonucleotides: A Preliminary Review Across Subcutaneous, Intravenous & Intrathecal Routes of Administration
Favorite
5:00 PM – 7:00 PM
ET
095: A Survey of Pharmacodynamic Biomarkers Bioanalysis in 20 Biologics License Applications Approved for Enzyme Replacement Therapy Indications
Favorite
5:00 PM – 7:00 PM
ET
096: Cluster Analysis to Identify Biomarkers of Treatment Response Following Sirolimus Treatment for HIV Cure
Favorite
5:00 PM – 7:00 PM
ET
097: Comparison of Hypoxia Inducible Factor-1A Polymorphisms Between Chronic Kidney Disease Patients & Healthy Subjects
Favorite
5:00 PM – 7:00 PM
ET
098: CYP2B6 & CYP2C19 Phenotypes Influence Sertraline Exposure in Children & Adolescents
Favorite
5:00 PM – 7:00 PM
ET
100: Sex-Related Differences in the Pharmacokinetics of Therapeutic Proteins
Favorite
5:00 PM – 7:00 PM
ET
101: The SARS-CoV-2 Mpro Inhibitor Ibuzatrelvir is a Substrate but not an Inducer nor Inhibitor of CYP3A
Favorite
5:00 PM – 7:00 PM
ET
102: Sisunatovir Inhibition of Multiple Ion Channel Subtypes Prevents the Risk for QT Prolongation Due to hERG Channel Inhibition
Favorite
5:00 PM – 7:00 PM
ET
105: ENA-001, a Novel BK-channel Blocker, Enhances Hypoxic Ventilatory Sensitivity and Alleviates Propofol-induced Respiratory Effects in Healthy Volunteers
Favorite
5:00 PM – 7:00 PM
ET
106: First-in-Human Safety, Pharmacokinetics & Pharmacodynamics of the Oral Factor D Inhibitor BCX10013
Favorite
5:00 PM – 7:00 PM
ET
107: Pharmacokinetic & Immunogenicity Results from the China Cohort of the MAJESTEC-1 Study of Teclistamab for Relapsed/refractory Multiple Myeloma
Favorite
5:00 PM – 7:00 PM
ET
108: Pharmacokinetic Comparison of Ezetimibe/Rosuvastatin/Telmisartan Fixed-dose Combination vs Coadministration of Separate Treatments
Favorite
5:00 PM – 7:00 PM
ET
109: Pharmacokinetic Comparison Between Fixed-dose Combination of Rosuvastatin/Ezetimibe 2.5/10 mg & the Coadministration of Individual Formulations in Healthy Subjects
Favorite
5:00 PM – 7:00 PM
ET
110: Phase 1, Single-Center, Randomized, Placebo-Controlled, Partially Blinded, Single Ascending Dose Study on the Effects of Troriluzole on corrected QT in Healthy Subjects
Favorite
5:00 PM – 7:00 PM
ET
111: Effect of Food on the Pharmacokinetics, Safety & Tolerability of Budesonide Oral Suspension in Healthy Adults: A Randomized Phase 1 Study
Favorite
5:00 PM – 7:00 PM
ET
112: Pharmacokinetics & Safety of Teclistamab Administered in the Arm or Thigh of Patients With Relapsed/Refractory Multiple Myeloma in MajesTEC-1
Favorite
5:00 PM – 7:00 PM
ET
113: Pharmacokinetics, Safety & Tolerability of GS-1427, a Pro-drug of a Potent & Selective Small-Molecule α4β7 Integrin Inhibitor, in Healthy Volunteers
Favorite
5:00 PM – 7:00 PM
ET
114: Pharmacokinetic Characterization of Flotetuzumab in Pediatric Patients With Refractory/Relapsed Acute Myeloid Leukemia
Favorite
5:00 PM – 7:00 PM
ET
115: The Effectiveness of Anmarin, an Antimycotic Herbal Drug: Preclinical & Clinical Studies
Favorite
5:00 PM – 7:00 PM
ET
116: Addressing Disparities in Clinical Trial Participation: A Comparative Analysis of Cardiovascular & Oncology Studies
Favorite
5:00 PM – 7:00 PM
ET
117: Analyzing Drug-Drug Interaction Risk Assessment Strategies for Protein Therapeutics in Inflammatory Bowel Disease: A Literature-Based Evidence Review
Favorite
5:00 PM – 7:00 PM
ET
118: Evaluation of Drug-Drug Interaction in Nested Patient Studies
Favorite
5:00 PM – 7:00 PM
ET
119: Quantitative Assessment of Drug-Drug Interaction (DDI) Potential of BIIB122 on Oral Contraceptives Using a Physiologically-based Ppharmacokinetic Model
Favorite
5:00 PM – 7:00 PM
ET
120: Effect of Herbal Medicines on the Pharmacokinetics of Donepezil
Favorite
5:00 PM – 7:00 PM
ET
121: Organic Anion Transporter 3 Mediated Interactions in a Renal Proximal Tubule Epithelial Cellular Model: Effects of Mycophenolate & Prednisolone
Favorite
5:00 PM – 7:00 PM
ET
122: A Literature Review on the Performance of Tiny Tract for In Vitro Modeling to Predict Food-Drug & pH-Dependent Drug-Drug Interaction Risks
Favorite
5:00 PM – 7:00 PM
ET
123: Assessment of Impact of CYP3A4 Inducers on Investigational Drugs Informed By Clinical Drug-Drug Interaction Data: A Survey of Drugs Approved By FDA
Favorite
5:00 PM – 7:00 PM
ET
124: A Drug-Drug Interaction Study to Evaluate the Impact of Coadministration of AZD0780 on Rosuvastatin Exposure in Healthy Participants
Favorite
5:00 PM – 7:00 PM
ET
125: Pregabalin-codeine-disease Interactions in Patients With Acute Herpetic or Postherpetic Neuralgia
Favorite
5:00 PM – 7:00 PM
ET
126: Effect of a Moderate CYP3A4 Inducer on the Pharmacokinetics of Omaveloxolone in Healthy Subjects
Favorite
5:00 PM – 7:00 PM
ET
127: Phase I Open Label Study to Evaluate the Effects of Strong CYP1A2 Inhibitor on Savolitinib Pharmacokinetics in Healthy Volunteers
Favorite
5:00 PM – 7:00 PM
ET
128: Food & Formulation Effect of a Novel Src Homology Region 2 Domain−containing Protein Tyrosine Phosphatase 2 (SHP2) Allosteric Inhibitor in Combination With Pembrolizumab
Favorite
5:00 PM – 7:00 PM
ET
129: Identification of Factors Associated With Vancomycin-Induced Acute Kidney Injury: An Analysis Using a Common Data Model
Favorite
5:00 PM – 7:00 PM
ET
130: Clinical Outcomes of Carfilzomib-based Chemotherapy by Relative Dose Intensity in Patients with Relapsed or Refractory Multiple Myeloma
Favorite
5:00 PM – 7:00 PM
ET
131: Network Analysis of Sedative Medication Use in a Canadian Cohort of People Living with HIV: Uncovering Potential Sedative Medication Drivers of Frailty States
Favorite
5:00 PM – 7:00 PM
ET
132: Strategic Selection of Clinical Trial Core Outcomes Customized to Disease & Drug Therapy: Examples Generated During coreVWD & coreHEM Initiatives
Favorite
5:00 PM – 7:00 PM
ET
133: Effect of Probiotics on the Levels of Neuroendocrine Biomarkers – A Systematic Review & Meta-Analysis
Favorite
5:00 PM – 7:00 PM
ET
135: Population Kinetic-Pharmacodynamic Modeling of Multiple Lipid Biomarker Responses to Zodasiran in Patients With Mixed Dyslipidemia
Favorite
5:00 PM – 7:00 PM
ET
136: Population Pharmacokinetics & Pharmacodynamics of Pegozafermin, a Novel GlycoPEGylated FGF21, in a Phase 2 Study in Severe Hypertriglyceridemia
Favorite
5:00 PM – 7:00 PM
ET
137: Application of Lactation Physiologically-based Pharmacokinetic Modeling to Predict Exposure of Select Compounds
Favorite
5:00 PM – 7:00 PM
ET
138: Exposure-Response Analyses of Efficacy & Safety of Trastuzumab Deruxtecan to Inform Dosing Recommendation in HER2-mutant Non-Small Cell Lung Cancer
Favorite
5:00 PM – 7:00 PM
ET
139: Imaging-based Anti-HIV Antibody Exposure in Anorectal Tissue Is More Closely Linked to Protective Efficacy During Clinical Prevention Trials
Favorite
5:00 PM – 7:00 PM
ET
140: Pharmacokinetic-Pharmacodynamic Analysis of Cytokines in First-in-Human Phase 1 Dose Escalation Study of the MALT-1 Inhibitor, SGR-1505, in Healthy Volunteers
Favorite
5:00 PM – 7:00 PM
ET
141: A Comparative Analysis of Pharmacokinetics of Oncology Drugs Between Healthy Volunteers & Patients With Cancer
Favorite
5:00 PM – 7:00 PM
ET
142: Landscape Analysis of Dose Optimization Approaches in Oncology Investigational New Drug (IND) Submissions in 2023
Favorite
5:00 PM – 7:00 PM
ET
143: The Effect of Severe Renal Impairment on ONC201 (Dordaviprone) Pharmacokinetics
Favorite
5:00 PM – 7:00 PM
ET
144: Population Pharmacokinetic Model for Tulisokibart in Healthy Participants
Favorite
5:00 PM – 7:00 PM
ET
145: Physiologically-based Pharmacokinetic Models of Opioid in Pregnancy, Maternal-Fetal, Pediatrics & Breastfeeding Mothers: A Systematic Literature Review
Favorite
5:00 PM – 7:00 PM
ET
146: Optimizing Simvastatin Dosing in Patients Post-gastric Bypass Surgery Using a Population PK/PD Link Approach
Favorite
5:00 PM – 7:00 PM
ET
147: Real-World Insights into Drug Dosing Patterns for Commonly Prescribed Drugs During Pregnancy
Favorite
5:00 PM – 7:00 PM
ET
148: The Mechanism of Action of an Innovative Respiratory Stimulant, ENA-001
Favorite
5:00 PM – 7:00 PM
ET
149: Milvexian Does Not Prolong the QTc Interval: A Thorough QT Study in Healthy Subjects
Favorite
5:00 PM – 7:00 PM
ET
151: Genome-Wide CpG Methylation Profiling of Leukemia Cells Treated With Curcuminoids
Favorite
5:00 PM – 7:00 PM
ET
152: Pharmacoeconomic Analysis of Therapeutic Regimens Used for Treatment of Psoriasis in India
Favorite
5:00 PM – 7:00 PM
ET
153: Population Pharmacokinetics/Pharmacodynamics Modeling of INCAGN02385 in Patients With Select Advanced Malignancies
Favorite
5:00 PM – 7:00 PM
ET
154: Pharmacokinetics of Sacituzumab Govitecan in Japanese Patients With Advanced Solid Tumors
Favorite
5:00 PM – 7:00 PM
ET
155: The Human Metabolism of Lufotrelvir, a Prodrug for the Treatment of SARS-COV2, Investigated By LC+AMS
Favorite
5:00 PM – 7:00 PM
ET
156: Comparable Pharmacokinetics of Sacituzumab Govitecan Between Patients With Metastatic Urothelial Cancer & Metastatic Triple-Negative Breast Cancer
Favorite
5:00 PM – 7:00 PM
ET
157: Pharmacokinetics & Exposure-Response Analyses of Revumenib Support Dosing in a Broad Population of Patients With Relapsed/Refractory Acute Leukemias
Favorite
5:00 PM – 7:00 PM
ET
158: Model-Informed Development of Recombinant
Erwinia
Asparaginase (JZP458) in Patients With Acute Lymphoblastic Leukemia
Favorite
5:00 PM – 7:00 PM
ET
159: Pharmacokinetics, Pharmacodynamics & Safety of Budigalimab, An Anti-PD-1 Monoclonal Antibody, in People Living With HIV-1
Favorite
5:00 PM – 7:00 PM
ET
160: Modeling Age-related Changes in Kidney Function Using Aminoglycoside Clearance as a Surrogate: Can Body Composition Help?
Favorite
5:00 PM – 7:00 PM
ET
161: Comparison of Nicotine Pharmacokinetic & Subjective Profiles of Three Modern Oral Nicotine Products & a Snus Product
Favorite
5:00 PM – 7:00 PM
ET
162: Pharmacokinetics of DYP688 in Patients With Metastatic Uveal Melanoma & Other GNAQ/11 Mutant Melanomas
Favorite
5:00 PM – 7:00 PM
ET
163: GLP-1-Induced Delays in GI Motility & Their Effects on Co-Administered Drug Absorption: A PBPK Analysis
Favorite
5:00 PM – 7:00 PM
ET
164: No Clinically Relevant Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Lirafugratinib
Favorite
5:00 PM – 7:00 PM
ET
165: Demographic Composition of New Molecular Entities Approved by the United States FDA Between 2017 & 2023 to Treat Type 2 Diabetes
Favorite
5:00 PM – 7:00 PM
ET
166: Fetal & Neonatal Drug Exposure Following Nipocalimab Treatment in Pregnant Women at Risk of EOS-HDFN
Favorite
5:00 PM – 7:00 PM
ET
167: Acetaminophen Prescribing & Pharmacokinetic Analysis in Children, Adolescents & Young Adults With Cancer
Favorite
